{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T13:02:54Z","timestamp":1784206974287,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB\/TRR 57"],"award-info":[{"award-number":["SFB\/TRR 57"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Spanish Ministry of Science","award":["FJC2018-036199-I"],"award-info":[{"award-number":["FJC2018-036199-I"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s00467-022-05836-3","type":"journal-article","created":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T08:04:03Z","timestamp":1670313843000},"page":"2083-2092","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Three Tesla magnetic resonance imaging detects oxalate osteopathy in patients with primary hyperoxaluria type I"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0325-3818","authenticated-orcid":false,"given":"Lisa-Marie","family":"Merz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1740-0006","authenticated-orcid":false,"given":"Mark","family":"Born","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6306-3170","authenticated-orcid":false,"given":"Guido","family":"Kukuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1435-9562","authenticated-orcid":false,"given":"Alois M.","family":"Sprinkart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5829-3553","authenticated-orcid":false,"given":"Ingrid","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1139-4642","authenticated-orcid":false,"given":"Cristina","family":"Martin-Higueras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8120-3306","authenticated-orcid":false,"given":"Bernd","family":"Hoppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,6]]},"reference":[{"key":"5836_CR1","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1517\/14656566.7.14.1887","volume":"7","author":"AE Bobrowski","year":"2006","unstructured":"Bobrowski AE, Langman CB (2006) Hyperoxaluria and systemic oxalosis: current therapy and future directions. Expert Opin Pharmacother 7:1887\u20131896. https:\/\/doi.org\/10.1517\/14656566.7.14.1887","journal-title":"Expert Opin Pharmacother"},{"key":"5836_CR2","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/ki.2009.32","volume":"75","author":"B Hoppe","year":"2009","unstructured":"Hoppe B, Beck BB, Milliner DS (2009) The primary hyperoxalurias. Kidney Int 75:1264\u20131271. https:\/\/doi.org\/10.1038\/ki.2009.32","journal-title":"Kidney Int"},{"key":"5836_CR3","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nrneph.2012.113","volume":"8","author":"B Hoppe","year":"2012","unstructured":"Hoppe B (2012) An update on primary hyperoxaluria. Nat Rev Nephrol 8:467\u2013475. https:\/\/doi.org\/10.1038\/nrneph.2012.113","journal-title":"Nat Rev Nephrol"},{"key":"5836_CR4","doi-asserted-by":"publisher","first-page":"687658","DOI":"10.1155\/2013\/687658","volume":"2013","author":"AL Pey","year":"2013","unstructured":"Pey AL, Albert A, Salido E (2013) Protein homeostasis defects of alanine-glyoxylate aminotransferase: new therapeutic strategies in primary hyperoxaluria type I. Biomed Res Int 2013:687658. https:\/\/doi.org\/10.1155\/2013\/687658","journal-title":"Biomed Res Int"},{"key":"5836_CR5","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/ndt\/18.2.273","volume":"18","author":"CS van Woerden","year":"2003","unstructured":"van Woerden CS, Groothoff JW, Wanders RJA, Davin JC, Wijburg FA (2003) Primary hyperoxaluria type 1 in The Netherlands: prevalence and outcome. Nephrol Dial Transplant 18:273\u2013279. https:\/\/doi.org\/10.1093\/ndt\/18.2.273","journal-title":"Nephrol Dial Transplant"},{"key":"5836_CR6","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1681\/ASN.2014070698","volume":"26","author":"K Hopp","year":"2015","unstructured":"Hopp K, Cogal AG, Bergstralh EJ, Seide BM,\u00a0Olson JB, Meek AM, Lieske JC, Milliner DM, Harris PC (2015) Phenotype-Genotype correlations and estimated carrier frequencies of primary hyperoxaluria. J Am Soc Nephrol 26:2559\u20132570. https:\/\/doi.org\/10.1681\/ASN.2014070698","journal-title":"J Am Soc Nephrol"},{"key":"5836_CR7","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/s0140-6736(86)90584-2","volume":"2","author":"CJ Danpure","year":"1968","unstructured":"Danpure CJ (1968) Peroxisomal alanine:glyoxylate aminotransferase and prenatal diagnosis of primary hyperoxaluria type 1. Lancet 2:1168. https:\/\/doi.org\/10.1016\/s0140-6736(86)90584-2","journal-title":"Lancet"},{"key":"5836_CR8","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s00467-006-0124-4","volume":"21","author":"P Cochat","year":"2006","unstructured":"Cochat P, Liutkus A, Fargue S, Basmaison O, Ranchin B, Rolland MO (2006) Primary hyperoxaluria type 1: still challenging! Pediatr Nephrol 21:1075\u20131081. https:\/\/doi.org\/10.1007\/s00467-006-0124-4","journal-title":"Pediatr Nephrol"},{"key":"5836_CR9","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/ki.2013.207","volume":"84","author":"F Knauf","year":"2013","unstructured":"Knauf F, Asplin JR, Granja I,\u00a0Schmidt IM, Moeckel GW, David RJ, Flavell RA, Aronson PS (2013) NALP3-mediated inflammation is a principal cause of progressive renal failure in oxalate nephropathy. Kidney Int 84:895\u2013901. https:\/\/doi.org\/10.1038\/ki.2013.207","journal-title":"Kidney Int"},{"key":"5836_CR10","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1046\/j.1523-1755.1998.00066.x","volume":"54","author":"B Hoppe","year":"1998","unstructured":"Hoppe B, Kemper MJ, Bokenkamp A, Langman CB (1998) Plasma calcium-oxalate saturation in children with renal insufficiency and in children with primary hyperoxaluria. Kidney Int 54:921\u2013925. https:\/\/doi.org\/10.1046\/j.1523-1755.1998.00066.x","journal-title":"Kidney Int"},{"key":"5836_CR11","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1093\/ndt\/16.11.2236","volume":"16","author":"B Behnke","year":"2001","unstructured":"Behnke B, Kemper MJ, Kruse HP, M\u00fcller-Wiefel DE (2001) Bone mineral density in children with primary hyperoxaluria type I. Nephrol Dial Transplant 16:2236\u20132239. https:\/\/doi.org\/10.1093\/ndt\/16.11.2236","journal-title":"Nephrol Dial Transplant"},{"key":"5836_CR12","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1136\/adc.82.6.470","volume":"82","author":"P Cochat","year":"2000","unstructured":"Cochat P, Basmaison O (2000) Current approaches to the management of primary hyperoxaluria. Arch Dis Child 82:470\u2013473. https:\/\/doi.org\/10.1136\/adc.82.6.470","journal-title":"Arch Dis Child"},{"key":"5836_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00467-015-3048-z","volume":"31","author":"J Bacchetta","year":"2016","unstructured":"Bacchetta J, Boivin G, Cochat P (2016) Bone impairment in primary hyperoxaluria: a review. Pediatr Nephrol 31:1\u20136. https:\/\/doi.org\/10.1007\/s00467-015-3048-z","journal-title":"Pediatr Nephrol"},{"key":"5836_CR14","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/BF01095951","volume":"5","author":"CM Schnitzler","year":"1991","unstructured":"Schnitzler CM, Kok JA, Jacobs DW,\u00a0Thomson PD, Milne FJ, Mesquita JM, King PC, Fabian VA (1991) Skeletal manifestations of primary oxalosis. Pediatr Nephrol 5:193\u2013199. https:\/\/doi.org\/10.1007\/BF01095951","journal-title":"Pediatr Nephrol"},{"key":"5836_CR15","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1038\/sj.ki.5001758","volume":"70","author":"V Lorenzo","year":"2006","unstructured":"Lorenzo V, Alvarez A, Torres A, Torregrosa V, Hern\u00e1ndez D, Salido E (2006) Presentation and role of transplantation in adult patients with type 1 primary hyperoxaluria and the I244T AGXT mutation: Single-center experience. Kidney Int 70:1115\u20131119. https:\/\/doi.org\/10.1038\/sj.ki.5001758","journal-title":"Kidney Int"},{"issue":"Suppl 3","key":"5836_CR16","doi-asserted-by":"publisher","first-page":"S164","DOI":"10.2215\/CJN.00460107","volume":"3","author":"JD Hernandez","year":"2008","unstructured":"Hernandez JD, Wesseling K, Pereira R, Gales B, Harrison R, Salusky IB (2008) Technical approach to iliac crest biopsy. Clin J Am Soc Nephrol 3(Suppl 3):S164-169. https:\/\/doi.org\/10.2215\/CJN.00460107","journal-title":"Clin J Am Soc Nephrol"},{"key":"5836_CR17","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","volume":"384","author":"SF Garrelfs","year":"2021","unstructured":"Garrelfs SF, Frishberg Y, Hulton SA, Koren MJ, O'Riordan WD, Cochat P, Desch\u00eanes G, Shasha-Lavsky H, Saland JM, Van't Hoff WG, Fuster DG, Magen D, Moochhala SH, Schalk G, Simkova E, Groothoff JW, Sas DJ, Meliambro KA, Lu J, Sweetser MT, Garg PP, Vaishnaw AK, Gansner JM, McGregor TL, Lieske JC; ILLUMINATE-A Collaborators\u00a0 (2021) Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. N Engl J Med 384:1216\u20131226. https:\/\/doi.org\/10.1056\/NEJMoa2021712","journal-title":"N Engl J Med"},{"key":"5836_CR18","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.kint.2021.08.015","volume":"101","author":"B Hoppe","year":"2022","unstructured":"Hoppe B, Koch A, Cochat P, Garrelfs SF, Baum MA, Groothoff JW, Lipkin G, Coenen M, Schalk G, Amrite A, McDougall D, Barrios K, Langman CB (2022) Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria. Kidney Int 101:626\u2013634. https:\/\/doi.org\/10.1016\/j.kint.2021.08.015","journal-title":"Kidney Int"},{"key":"5836_CR19","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1159\/000080254","volume":"98","author":"CJ Danpure","year":"2004","unstructured":"Danpure CJ (2004) Molecular aetiology of primary hyperoxaluria type 1. Nephron Exp Nephrol 98:e39-44. https:\/\/doi.org\/10.1159\/000080254","journal-title":"Nephron Exp Nephrol"},{"key":"5836_CR20","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1002\/humu.21021","volume":"30","author":"EL Williams","year":"2009","unstructured":"Williams EL, Acquaviva C, Amoroso A, Chevalier F, Coulter-Mackie M, Monico CG, Giachino D, Owen T, Robbiano A, Salido E, Waterham H, Rumsby G (2009) Primary hyperoxaluria type 1: update and additional mutation analysis of the AGXT gene. Hum Mutat 30:910\u2013917. https:\/\/doi.org\/10.1002\/humu.21021","journal-title":"Hum Mutat"},{"key":"5836_CR21","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","volume":"20","author":"GJ Schwartz","year":"2009","unstructured":"Schwartz GJ, Mu\u00f1oz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629\u2013637. https:\/\/doi.org\/10.1681\/ASN.2008030287","journal-title":"J Am Soc Nephrol"},{"key":"5836_CR22","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604\u2013612. https:\/\/doi.org\/10.7326\/0003-4819-150-9-200905050-00006","journal-title":"Ann Intern Med"},{"key":"5836_CR23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/kisup.2012.77","volume":"3","author":"KDIGO","year":"2013","unstructured":"KDIGO (2013) KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3:5\u201314","journal-title":"Kidney Int Suppl"},{"key":"5836_CR24","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1046\/j.1523-1755.1999.00546.x","volume":"56","author":"B Hoppe","year":"1999","unstructured":"Hoppe B, Kemper MJ, B\u00f6kenkamp A, Portale AA, Cohn RA, Langman CB (1999) Plasma calcium oxalate supersaturation in children with primary hyperoxaluria and end-stage renal failure. Kidney Int 56:268\u2013274. https:\/\/doi.org\/10.1046\/j.1523-1755.1999.00546.x","journal-title":"Kidney Int"},{"key":"5836_CR25","doi-asserted-by":"publisher","first-page":"5471","DOI":"10.1088\/0031-9155\/60\/14\/5471","volume":"60","author":"M Valli\u00e8res","year":"2015","unstructured":"Valli\u00e8res M, Freeman CR, Skamene SR, El Naqa I (2015) A radiomics model from joint FDG-PET and MRI texture features for the prediction of lung metastases in soft-tissue sarcomas of the extremities. Phys Med Biol 60:5471\u20135496. https:\/\/doi.org\/10.1088\/0031-9155\/60\/14\/5471","journal-title":"Phys Med Biol"},{"key":"5836_CR26","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s00247-016-3723-7","volume":"47","author":"SB Strauss","year":"2017","unstructured":"Strauss SB, Waltuch T, Bivin W, Kaskel F, Levin TL (2017) Primary hyperoxaluria: spectrum of clinical imaging findings. Pediatr Radiol 47:96\u2013103. https:\/\/doi.org\/10.1007\/s00247-016-3723-7","journal-title":"Pediatr Radiol"},{"key":"5836_CR27","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/BF00973200","volume":"12","author":"J Wiggelinkhuizen","year":"1982","unstructured":"Wiggelinkhuizen J, Fisher RM (1982) Oxalosis of bone. Pediatr Radiol 12:307\u2013309. https:\/\/doi.org\/10.1007\/BF00973200","journal-title":"Pediatr Radiol"},{"key":"5836_CR28","doi-asserted-by":"publisher","first-page":"935","DOI":"10.2214\/ajr.136.5.935","volume":"136","author":"D Brancaccio","year":"1981","unstructured":"Brancaccio D, Poggi A, Ciccarelli C, Bellini F, Galmozzi C, Poletti I, Maggiore (1981) Bone changes in end-stage oxalosis. AJR Am J Roentgenol 136:935\u2013939. https:\/\/doi.org\/10.2214\/ajr.136.5.935","journal-title":"AJR Am J Roentgenol"},{"key":"5836_CR29","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s11832-008-0082-4","volume":"2","author":"S El Hage","year":"2008","unstructured":"El Hage S, Ghanem I, Baradhi A, Mourani C, Mallat S, Dagher F, Kharrat K (2008) Skeletal features of primary hyperoxaluria type 1, revisited. J Child Orthop 2:205\u2013210. https:\/\/doi.org\/10.1007\/s11832-008-0082-4","journal-title":"J Child Orthop"},{"key":"5836_CR30","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1111\/ajt.16887","volume":"22","author":"A Devresse","year":"2022","unstructured":"Devresse A, Lhommel R, Godefroid N, Goffin E, Kanaan N (2022) 18-Fluorodeoxyglucose positron emission computed tomography for systemic oxalosis in primary hyperoxaluria type 1. Am J Transplant 22:1001\u20131002. https:\/\/doi.org\/10.1111\/ajt.16887","journal-title":"Am J Transplant"},{"key":"5836_CR31","doi-asserted-by":"publisher","first-page":"e296","DOI":"10.1097\/RLU.0000000000003047","volume":"45","author":"D Tonnelet","year":"2020","unstructured":"Tonnelet D, Benali K, Rasmussen C, Goulenok T, Piekarski E (2020) Diffuse hypermetabolic bone marrow infiltration in severe primary hyperoxaluria on FDG PET. Clin Nucl Med 45:e296\u2013e298. https:\/\/doi.org\/10.1097\/RLU.0000000000003047","journal-title":"Clin Nucl Med"},{"issue":"Suppl 1","key":"5836_CR32","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.3346\/jkms.2016.31.S1.S69","volume":"31","author":"HW Kwon","year":"2016","unstructured":"Kwon HW, Kim JP, Lee HJ, Paeng JC, Lee JS, Cheon GJ, Lee DS, Chung JK, Kang KW (2016) Radiation dose from whole-body F-18 fluorodeoxyglucose positron emission tomography\/computed tomography: nationwide survey in Korea. J Korean Med Sci 31(Suppl 1):S69-74. https:\/\/doi.org\/10.3346\/jkms.2016.31.S1.S69","journal-title":"J Korean Med Sci"},{"key":"5836_CR33","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1007\/s00467-019-04330-7","volume":"34","author":"R Lagies","year":"2019","unstructured":"Lagies R, Udink Ten Cate FEA, Feldk\u00f6tter M, Beck BB, Sreeram N, Hoppe B, Herberg U (2019) Subclinical myocardial disease in patients with primary hyperoxaluria and preserved left ventricular ejection fraction: a two-dimensional speckle-tracking imaging study. Pediatr Nephrol 34:2591\u20132600. https:\/\/doi.org\/10.1007\/s00467-019-04330-7","journal-title":"Pediatr Nephrol"},{"key":"5836_CR34","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.1093\/ndt\/gfs320","volume":"27","author":"SM Van Der Hoeven","year":"2012","unstructured":"Van Der Hoeven SM, Van Woerden CS, Groothoff JW (2012) Primary hyperoxaluria Type 1, a too often missed diagnosis and potentially treatable cause of end-stage renal disease in adults: results of the Dutch cohort. Nephrol Dial Transplant 27:3855\u20133862. https:\/\/doi.org\/10.1093\/ndt\/gfs320","journal-title":"Nephrol Dial Transplant"}],"updated-by":[{"DOI":"10.1007\/s00467-022-05868-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000}}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-022-05836-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-022-05836-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-022-05836-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T09:11:44Z","timestamp":1688980304000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-022-05836-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,6]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["5836"],"URL":"https:\/\/doi.org\/10.1007\/s00467-022-05836-3","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00467-022-05868-9","asserted-by":"object"}]},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,6]]},"assertion":[{"value":"12 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2023","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00467-022-05868-9","URL":"https:\/\/doi.org\/10.1007\/s00467-022-05868-9","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"BH has been an employee, and CMH is a consultant of Dicerna Pharmaceuticals, a Novo Nordisk subsidiary, Lexington, USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}